The absence of a biomarker for MS means that diagnosis is predicated on the exclusion of competing diagnoses and so, to date, reliable cell-based assays detecting antibodies against AQP4 and MOG remain the gold standard for diagnosing and differentiating these three conditions. Here, MOG is linked to myeloid sarcoma.